Innovent Biologics (HKSE:01801) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01801 Innovent Biologics Inc HKSE:01801
84 GF Score
Price HK$88.95
GF Value HK$100.93
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HKSE:01801 vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Innovent Biologics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Short Percentage of Float falls into.


HKSE:01801
84GF Score
Innovent Biologics Inc HKSE:01801
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innovent Biologics (HKSE:01801) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of HK$88.95 is trading 11.9% below its estimated GF Value™ of HK$100.93. GuruFocus considers Innovent Biologics to be Modestly Undervalued.

Key valuation signals for HKSE:01801:

  • Short Percentage of Float:
  • GF Value™: HK$100.93 vs. price of HK$88.95 (11.9% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the HKSE:01801 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
84GF Score

Get the complete analysis for HKSE:01801

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$88.95
Price
HK$100.93
GF Value